Stocks and Investing
Stocks and Investing
Wed, April 20, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, April 19, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jessica Fye Maintained (UTHR) at Buy with Decreased Target to $223 on, Apr 19th, 2022
Jessica Fye of JP Morgan, Maintained "United Therapeutics Corporation" (UTHR) at Buy with Decreased Target from $230 to $223 on, Apr 19th, 2022.
Jessica has made no other calls on UTHR in the last 4 months.
There are 3 other peers that have a rating on UTHR. Out of the 3 peers that are also analyzing UTHR, 1 agrees with Jessica's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Julian Harrison of "BTIG" Initiated at Hold on, Friday, February 11th, 2022
These are the ratings of the 2 analyists that currently disagree with Jessica
- Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $236 on, Monday, February 28th, 2022
- Matthew Kaplan of "Ladenburg Thalmann" Maintained at Strong Buy with Decreased Target to $203 on, Friday, February 25th, 2022
Contributing Sources